Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection
Authors
1Department of Internal Medicine & Imam Khomeini Hospital, Tehran University of Medical Sciences, mohssen_nasiri@yahoo.com, Tehran, IR.Iran
2Department of Otolyrngology Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR.Iran
*Corresponding Author: Department of Internal Medicine & Imam Khomeini Hospital, Tehran University of Medical Sciences, mohssen_nasiri@yahoo.com, Tehran, IR.Iran. Tel: 0098 21 801 2992. Fax: 0098 21 225 3635. Email: mohssen_nasiri@yahoo.com
How to Cite:Toosi M, Hassanabadi M. Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection. Hepat Mon. 2004;4(7):. doi:
Abstract
Hearing loss has been reported on interferons therapy. Combination therapy of pegylated (PEG)-IFN alfa2a plus ribavirin is the current optimal therapy for hepatitis C infection. PEG-INF side effect profile is reported similar in different studies, but with the increasing long-term use of PEG-INF several new adverse effects have been recognized. However, hearing loss has only been recorded once. We report a case of sensorineural hearing loss occurring in a patient with chronic hepatitis C treated with PEG-IFN plus ribavirin and recovered partially one month after the discontinuation of PEG-INF. The ototoxicity would be more serious with the use of PEG-INF. Patients on therapy with this drug should be monitored for auditory disability. The ototoxicity is reversible with discontinuation of drug if the diagnosis is made early in the course.
Highlights
KeywordsArticle
Copyright
© 2004, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
20
Feb
2014
Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and Ribavirin
Ligita Jancoriene,
Dovile Norvydaite,
Saulius Galgauskas,
Evelina Balciunaite
Jancoriene L, Norvydaite D, Galgauskas S, Balciunaite E. Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and Ribavirin. Hepat Mon. 2014;14(2):e15124. doi: https://doi.org/10.5812/hepatmon.15124
30
Sep
2004
Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
Mohammad Reza Zali,
Hamid Mohaghegh Shalmani,
Mohsen Norouzinia,
Amir Hooshang MohammadAlizadeh,
Azita Nowroozi,
Negar Behrouz
Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:
31
Jul
2012
Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea
Hyeong Il Kim,
In Hee Kim,
Byung Jun Jeon,
Seok Lee,
Seong Hun Kim,
Sang Wook Kim
,et al.Kim H, Kim I, Jeon B, Lee S, Kim S, et al. Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea. Hepat Mon. 2012;12(7):. doi: https://doi.org/10.5812/hepatmon.6170
20
Mar
2015
Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
Kamuran Turker,
Betul Tas,
Murat Ozkaya,
Ebru Tas,
Aysel Caglar,
Umit Seza Tetikkurt
Turker K, Tas B, Ozkaya M, Tas E, Caglar A, et al. Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy. Hepat Mon. 2015;15(3):e24804. doi: https://doi.org/10.5812/hepatmon.24804
30
Sep
2004
The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial
Nasser Ebrahimi Daryani,
Babak Haghpanah,
Ali Reza Sayyah,
Ali Asad Hashtroudi,
Mohammad Bashashati,
Parisa Poursamimi
,et al.Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 0
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 8 hours ago
- OpenAlex: 0
Last Update: 11 hours ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0